A method for inducing cells to secrete extracellular matrix and its application

Through specific inducer combinations and steps, the yield and protein content of inducing cells to secrete extracellular matrix is ​​improved, and the problems of low yield and insufficient efficiency in the prior art are solved, and efficient and protein-rich extracellular matrix production is achieved, enhancing the Its application value.

CN115478044BActive Publication Date: 2024-11-15GUANGZHOU ASIA KIDNEY REBUILDING MEDICAL TECH LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202211143637.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-20
Publication Date
2024-11-15
Estimated Expiration
2042-09-20

AI Technical Summary

Technical Problem

In the prior art, the yield and output efficiency of inducing cells to secrete extracellular matrix is ​​low, and the protein content is insufficient, making it difficult to meet the needs of industrial production. The obtained ECM quality is generally poor, especially the collagen content is small, which is lacking in application. sex.

Method used

Using specific inducer combinations and induction steps, including culturing cells in TeSR1 medium, followed by replacement with GSK-3α/β inhibitors, retinoic acid and fibroblast growth factor 2, activin A and fibroblast growth factor 9 The culture medium induces stem cells to secrete extracellular matrix, which significantly improves the yield and protein content of extracellular matrix through this method.

Benefits of technology

It has achieved efficient induction of human stem cells to secrete a large amount of extracellular matrix, with high protein content and significantly improved output efficiency. The obtained extracellular matrix is ​​rich in collagen, laminin and proteoglycan, enhancing its application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003854707980000011
    Figure HDA0003854707980000011
  • Figure HDA0003854707980000012
    Figure HDA0003854707980000012
  • Figure HDA0003854707980000021
    Figure HDA0003854707980000021
Patent Text Reader

Abstract

The present invention discloses a method for inducing cells to secrete extracellular matrix and its application. The method comprises the following steps: (1) culturing cells in a matrigel-coated cell culture container using TeSR1 culture medium; (2) replacing the culture medium with a cell culture medium containing CHIR99021 for 20 to 48 hours; (3) replacing the culture medium with a cell culture medium containing retinoic acid and fibroblast growth factor 2 for 20 to 48 hours; (4) replacing the culture medium with a cell culture medium containing activin A and fibroblast growth factor 9 for at least 1 day to obtain an extracellular matrix. The method can efficiently induce human pluripotent stem cells to secrete extracellular matrix, with high yield and a yield exceeding that of conventional methods. The obtained extracellular matrix has a higher protein content than the extracellular matrix obtained by conventional methods, and is rich in proteins and other active substances, and has a wider application prospect and better practicality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of cell culture, and particularly relates to a method for inducing cells to secrete extracellular matrix and an application thereof. Background Art

[0002] Extracellular matrix (ECM) is a macromolecular substance secreted by cells into the extracellular matrix, which can form a complex grid structure, thereby supporting and connecting tissue structure, regulating tissue development and cell physiological activities. The extracellular matrix is ​​mainly composed of five types of substances, including collagen, non-collagen, elastin, proteoglycan and aminoglycan. According to the distribution location, it is mainly divided into basement membrane and interstitial matrix.

[0003] Induced pluripotent stem cell (iPSC), also known as human induced pluripotent stem cell, often referred to as iPS cell (iPSC), is a pluripotent stem cell formed by dedifferentiation of mammalian adult cells through the transfer of transcription factors and other means.

[0004] At present, the methods for inducing cells to secrete ECM are relatively simple and cannot be separated from the use of inducers (such as ascorbic acid). In addition, the output and output efficiency of ECM are low, which is difficult to meet the needs of industrial production. In addition, the quality of ECM obtained by existing technologies is generally poor, and the protein content, especially the collagen content, is low, which is not applicable in the preparation of collagen using EMC. Summary of the invention

[0005] The present invention aims to solve the technical problem of inducing cells to secrete EMC, but the EMC yield is low and the protein content is low. To this end, the present invention provides a method for inducing cells to secrete extracellular matrix and its application. The method of the present invention is based on a specific inducer combination and induction steps, and can efficiently induce human stem cells to secrete extracellular matrix, with a large secretion amount and high secretion efficiency, and the obtained ECM is rich in a large amount of proteins and other active substances, including but not limited to collagen, laminin and proteoglycan.

[0006] The first aspect of the present invention provides a method for inducing stem cells to secrete extracellular matrix, comprising the following steps:

[0007] (1) Cultivating cells in a Matrigel-coated cell culture vessel using TeSR1 medium;

[0008] (2) Change to cell culture medium containing GSK-3α / β inhibitor and culture for 20 to 48 h;

[0009] (3) Change the cell culture medium to contain retinoic acid and fibroblast growth factor-2 and culture for 20 to 48 hours;

[0010] (4) The cell culture medium is replaced with one containing activin A and fibroblast growth factor-9 and cultured for at least 1 day to obtain the extracellular matrix.

[0011] In some embodiments of the present invention, the stem cells include human stem cells.

[0012] In the present invention, the term "human stem cells" refers to human stem cells, including related stem cells extracted from human bone marrow, fat, umbilical cord, placenta, and purified, proliferated, cultured, etc. in vitro.

[0013] In some embodiments of the present invention, the stem cells are human pluripotent stem cells.

[0014] In some embodiments of the invention, the stem cells are human pluripotent stem cells (iPSC) or human embryonic stem cells (ESC).

[0015] In some embodiments of the present invention, in step (2), the GSK-3α / β inhibitor is CHIR99021, and its final concentration in the stem cell culture medium is 5 to 15 μM.

[0016] In some embodiments of the present invention, in step (3), the final concentration of retinoic acid in the cell culture medium is 1 to 10 μM.

[0017] In some embodiments of the present invention, in step (3), the final concentration of the fibroblast growth factor 2 in the cell culture medium is 50 ng to 200 ng / mL.

[0018] In some embodiments of the present invention, in step (4), the final concentration of activin A in the cell culture medium is 1 to 10 ng / mL.

[0019] In some embodiments of the present invention, in step (4), the final concentration of the fibroblast growth factor 9 in the cell culture medium is 50 ng to 200 ng / mL.

[0020] In some embodiments of the present invention, the cell culture medium comprises RPMI 1640 medium.

[0021] In some embodiments of the present invention, the RPMI 1640 medium is w / L-glut RPMI 1640 medium. Of course, those skilled in the art can reasonably select other cell culture media for replacement according to actual use requirements, including but not limited to w / L-glut RPMI 1640 medium.

[0022] In some embodiments of the present invention, the matrix gel is a stem cell matrix gel.

[0023] In some embodiments of the present invention, the matrix glue is Vitronectin XF glue (embryonic stem cell culture adherent matrix). Of course, those skilled in the art can reasonably select other stem cell matrix glues to replace according to actual use requirements, including but not limited to Vitronectin XF glue.

[0024] In some embodiments of the present invention, the method is specifically:

[0025] (1) Cultivate cells in a Vitronectin XF gel-coated cell culture vessel using TeSR1 medium for 18 to 24 hours;

[0026] (2) Change to RPMI 1640 medium containing 5-15 μM CHIR99021 and culture for 20-48 h;

[0027] (3) changing to RPMI1640 medium containing 1-10 μM retinoic acid and 50 ng-200 ng / mL fibroblast growth factor-2 for 20-48 h;

[0028] (4) The culture medium was changed to RPMI 1640 medium containing 1-10 ng / mL activin A and 50 ng-200 ng / mL fibroblast growth factor-9 and cultured for at least 7 days to obtain extracellular matrix.

[0029] In some embodiments of the present invention, in step (4), the culture medium is replaced every 0.8 to 1.5 days.

[0030] In some embodiments of the present invention, in step (4), the culture medium is replaced once every day.

[0031] In some embodiments of the present invention, the method further comprises screening to remove impurities after step (4).

[0032] In some embodiments of the present invention, the step of sieving and removing impurities is: passing through a 40 μm cell sieve and removing the filtrate.

[0033] In the present invention, the inventors found that using the method of the present invention to treat stem cells can obtain more cells than conventional methods, and the amount of extracellular matrix produced by the cells is also significantly increased (on average, at least 18 mg of extracellular matrix is ​​produced per 10 million cells), thereby effectively improving the output efficiency of the extracellular matrix and increasing the economic value.

[0034] The second aspect of the present invention provides an extracellular matrix secreted by induction according to the method of the first aspect of the present invention, wherein the protein content of the extracellular matrix per milligram of matrix is ​​≥ 0.15 mg.

[0035] In the present invention, the inventors found that the extracellular matrix obtained by treating stem cells using the method of the present invention can secrete more proteins than the extracellular matrix obtained by conventional methods, thereby greatly enhancing the practical value and use effect of the extracellular matrix.

[0036] In some embodiments of the present invention, the protein concentration in the extracellular matrix is ​​greater than ≥1.60 mg / mL.

[0037] In some embodiments of the present invention, the extracellular matrix contains collagen, laminin and proteoglycan (GAG).

[0038] In some embodiments of the present invention, the collagen includes type I collagen, type II collagen, type III collagen and type IV collagen.

[0039] In the present invention, the inventors found that the extracellular matrix obtained by treating stem cells with the method of the present invention is rich in active substances, and contains not only various collagens, but also laminin and proteoglycan (GAG), and has extremely high application value.

[0040] The third aspect of the present invention provides use of the extracellular matrix described in the second aspect of the present invention in the preparation of a product containing at least one of collagen, laminin and proteoglycan.

[0041] In some embodiments of the present invention, the collagen includes type I collagen, type II collagen, type III collagen and type IV collagen.

[0042] In the present invention, the inventors found that the extracellular matrix obtained by treating stem cells using the method of the present invention is rich in active substances, which not only contains various collagens, but also laminin and proteoglycan (GAG). Therefore, related products can be further processed based on the extracellular matrix, thereby improving their application value.

[0043] In some embodiments of the present invention, the products include medicines, foods and cosmetics.

[0044] The beneficial effects of the present invention are:

[0045] (1) The present invention provides a method for inducing cells to secrete extracellular matrix. The method can efficiently induce human pluripotent stem cells to secrete extracellular matrix, has a short induction time, good induction effect, high extracellular matrix yield, and a yield that exceeds conventional methods.

[0046] (2) The extracellular matrix obtained in the present invention has a higher protein content than that obtained in conventional methods, and is rich in proteins and other active substances with richer types and stronger activity, including but not limited to type I collagen, type II collagen, type III collagen, type IV collagen, laminin and proteoglycans, and has broader application prospects and better practicality. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 This is a microscopic picture of iPSCs secreting extracellular matrix induced by the method in Example 1 of the present invention.

[0048] Figure 2 This is a macroscopic picture of iPSCs being induced to secrete extracellular matrix in a 6-well plate using the method in Example 1 of the present invention.

[0049] Figure 3 This is a microscopic picture of ESCs secreting extracellular matrix induced by the method in Example 2 of the present invention.

[0050] Figure 4 This is a microscopic picture of iPSCs secreting extracellular matrix induced by the method in Comparative Example 1 of the present invention.

[0051] Figure 5 This is a microscopic picture of iPSCs secreting extracellular matrix induced by the method in Comparative Example 2 of the present invention.

[0052] Figure 6 This is a microscopic picture of iPSCs secreting extracellular matrix induced by the method in Comparative Example 3 of the present invention.

[0053] Figure 7 These are the results of western blot of the extracellular matrix in Example 1 of the present invention. DETAILED DESCRIPTION

[0054] In order to make the invention purpose, technical solution and technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with specific implementation methods. It should be understood that the specific implementation methods described in this specification are only for explaining the present invention, not for limiting the present invention.

[0055] Unless otherwise specified, the experimental materials and reagents used are consumables and reagents that can be obtained from conventional commercial channels.

[0056] Example 1

[0057] The method for inducing cells to secrete ECM in this embodiment comprises the following steps:

[0058] (1) Matrigel coating:

[0059] The T75 culture flask was coated with Matrigel. Specifically, 400 μL of Vitronectin XF gel was diluted with 10 mL of Vitronectin XF buffer, and 6 mL of the diluted Matrigel was taken to the T75 culture flask for coating.

[0060] (2) Human pluripotent stem cells (iPSCs) were seeded in a culture flask coated with Matrigel at a cell seeding volume of 3.0×10 6 Add TeSR1 medium and culture the cells in a 37°C, 5% CO2 incubator for 24 hours.

[0061] (3) Replace with fresh 1×w / L-glut RPMI 1640 medium, add CHIR99021 (GSK-3α / β inhibitor, the final concentration in the medium is 5 μM), and culture the induced cells in a 37°C, 5% CO2 incubator for 36 hours.

[0062] (4) Replace with fresh 1×w / L-glut RPMI 1640 medium, add retinoic acid (RA) and fibroblast growth factor 2 (FGF2). The final concentration of RA in the medium is 1 μM, and the final concentration of FGF2 in the medium is 100 ng / mL. The induction culture time is 36 hours.

[0063] (5) Replace with fresh 1×w / L-glut RPMI 1640 medium, add Activin-A and fibroblast growth factor 9 (FGF9). The final concentration of Activin-A in the medium is 10 ng / ml, and the final concentration of FGF9 in the medium is 100 ng / mL. Induce culture for 7 days (Day, d), that is, until the 11th day from the start of culture, to induce secretion of extracellular matrix. During this period, change the medium once a day according to step (5).

[0064] The culture conditions at different induction stages (days, induction culture starts from step (3)) are as follows: Figure 1 shown.

[0065] It can be found that in the first 1 to 3 days after the induction culture, the cells were not covered with any matrix. Starting from the 4th day (i.e. after the addition of activin A and FGF9), the cells gradually began to be covered with matrix. On the 10th day, the matrix basically covered the cell surface, forming a hill-like protrusion.

[0066] On the 11th day after the start of culture, the cells were collected and passed through a 40 μm cell sieve, and the sieve residue (filter residue) was taken, which was the extracellular matrix.

[0067] In this example, by analyzing the material after culture, it was found that 3.5×10 cells were collected. 7 Each cell produced 73 mg of extracellular matrix (wet weight, weighing the material on the sieve). That is, on average, every 10 million cells produced about 20.86 mg of extracellular matrix.

[0068] The inventors used 6-well plates instead of T75 culture flasks to culture iPSCs and found that the same effect could be achieved. The extracellular matrix collected was as follows: Figure 2 shown.

[0069] Example 2

[0070] The method for inducing cells to secrete ECM in this embodiment comprises the following steps:

[0071] (1) Matrigel coating:

[0072] The T75 culture flask was coated with Matrigel. Specifically, 400 μL of Vitronectin XF gel was diluted with 10 mL of Vitronectin XF buffer, and 6 mL of the diluted Matrigel was taken to the T75 culture flask for coating.

[0073] (2) Human embryonic stem cells (ESCs) were seeded in a culture flask coated with Matrigel at a cell seeding volume of 3.0×10 6 Add TeSR1 medium and culture the cells in a 37°C, 5% CO2 incubator for 24 hours.

[0074] (3) Replace the medium with fresh 1×w / L-glut RPMI 1640, add CHIR99021 (final concentration in the medium is 10 μM), and culture the induced cells in a 37°C, 5% CO2 incubator for 38 hours.

[0075] (4) Replace with fresh 1×w / L-glut RPMI 1640 medium, add retinoic acid (RA) and fibroblast growth factor 2 (FGF2). The final concentration of RA in the medium is 5 μM, and the final concentration of FGF2 in the medium is 50 ng / mL. The induction culture time is 36 hours.

[0076] (5) Replace with fresh 1×w / L-glut RPMI 1640 medium, add Activin-A and fibroblast growth factor 9 (FGF9). The final concentration of Activin-A in the medium is 5 ng / ml, and the final concentration of FGF9 in the medium is 50 ng / mL. Induce culture for 7 days to induce secretion of extracellular matrix. During this period, change the medium once a day according to step (5).

[0077] The culture conditions at different induction stages (days, induction culture starts from step (3)) are as follows: Figure 3 shown.

[0078] It can be found that in the first 1 to 3 days after the induction culture, the cells were not covered with any matrix. Starting from the 4th day (i.e. after the addition of activin A and FGF9), the cells gradually began to be covered with matrix. On the 10th day, the matrix basically covered the cell surface, forming a hill-like protrusion.

[0079] On the 11th day after the start of culture, the cells were collected and passed through a 40 μm cell sieve, and the sieve residue (filter residue) was taken, which was the extracellular matrix.

[0080] In this example, by analyzing the substances after culture, it was found that a total of 2.8×10 cells were collected. 7 Each cell produced 53 mg of extracellular matrix (wet weight, weighing the material on the sieve). That is, on average, every 10 million cells produced about 18.90 mg of extracellular matrix.

[0081] Comparative Example 1

[0082] The method for inducing cells to secrete ECM in Comparative Example 1 is the same as that in Example 1, except that: no inducer is used in Comparative Example 1.

[0083] The specific steps are:

[0084] (1) Matrigel coating:

[0085] The T75 culture flask was coated with Matrigel. Specifically, 400 μL of Vitronectin XF gel was diluted with 10 mL of Vitronectin XF buffer, and 6 mL of the diluted Matrigel was taken to the T75 culture flask for coating.

[0086] (2) Human pluripotent stem cells (iPSCs) were seeded in a culture flask coated with Matrigel at a cell seeding volume of 3.0×10 6 TeSR1 medium was added, and the cells were cultured for a long time in a 37° C., 5% CO 2 incubator (the culture period was the same as in Example 1, and the culture environment and culture medium replacement were carried out according to the routine in the art).

[0087] The results are as follows Figure 4 shown.

[0088] It was found that even long-term culture of iPSCs (10 days) without the use of inducers did not induce the cells to secrete extracellular matrix.

[0089] Comparative Example 2

[0090] The method for inducing cells to secrete ECM in Comparative Example 2 is the same as that in Example 1, except that retinoic acid is not added.

[0091] The specific steps are:

[0092] (1) Matrigel coating:

[0093] The T75 culture flask was coated with Matrigel. Specifically, 400 μL of Vitronectin XF gel was diluted with 10 mL of Vitronectin XF buffer, and 6 mL of the diluted Matrigel was taken to the T75 culture flask for coating.

[0094] (2) Human pluripotent stem cells (iPSCs) were seeded in a culture flask coated with Matrigel at a cell seeding volume of 3.0×10 6 Add TeSR1 medium and culture the cells in a 37°C, 5% CO2 incubator for 24 hours.

[0095] (3) Replace the medium with fresh 1×w / L-glut RPMI 1640, add CHIR99021 (final concentration in the medium is 5 μM), and culture the induced cells in a 37°C, 5% CO2 incubator for 36 hours.

[0096] (4) Replace the culture medium with fresh 1×w / L-glut RPMI 1640 and add fibroblast growth factor 2 (FGF2). The final concentration of FGF2 in the culture medium is 100 ng / mL. The induction culture time is 36 hours.

[0097] (5) Replace with fresh 1×w / L-glut RPMI 1640 medium, add Activin-A and fibroblast growth factor 9 (FGF9). The final concentration of Activin-A in the medium is 10 ng / ml, and the final concentration of FGF9 in the medium is 100 ng / mL. Induce culture for 7 days (until the 11th day of culture) to induce secretion of extracellular matrix. During this period, change the medium once a day according to step (5).

[0098] The culture conditions at different induction stages (days, induction culture starts from step (2)) are as follows: Figure 5 shown.

[0099] It can be found that on the first 1 to 3 days after the induction culture, the cells were not covered with any matrix. Starting from the 4th day (i.e. after the addition of activin A and FGF9), the cells still did not produce any matrix. On the 7th day, matrix was visible on the surface of some cells. On the 10th day, a small amount of matrix was covered on the cell surface.

[0100] On the 11th day after the start of culture, the cells were collected and passed through a 40 μm cell sieve, and the sieve residue (filter residue) was taken, which was the extracellular matrix.

[0101] In this example, by analyzing the substances after culture, it was found that a total of 2.0×10 cells were collected. 7 Each cell produced 21 mg of extracellular matrix (wet weight, weigh the material on the sieve). That is, on average, every 10 million cells produced about 10.50 mg of extracellular matrix.

[0102] It can be found that in the absence of retinoic acid, the efficiency of cells producing extracellular matrix decreased significantly, indicating that retinoic acid can cooperate with FGF9 to enhance the efficiency of cells producing extracellular matrix.

[0103] Comparative Example 3

[0104] The method for inducing cells to secrete ECM in Comparative Example 3 is the same as that in Example 1, except that FGF2 is not added (step (4)).

[0105] The specific steps are:

[0106] (1) Matrigel coating:

[0107] The T75 culture flask was coated with Matrigel. Specifically, 400 μL of Vitronectin XF gel was diluted with 10 mL of Vitronectin XF buffer, and 6 mL of the diluted Matrigel was taken to the T75 culture flask for coating.

[0108] (2) Human pluripotent stem cells (iPSCs) were seeded in a culture flask coated with Matrigel at a cell seeding volume of 3.0×10 6 Add TeSR1 medium and culture the cells in a 37°C, 5% CO2 incubator for 24 hours.

[0109] (3) Replace the medium with fresh 1×w / L-glut RPMI 1640, add CHIR99021 (final concentration in the medium is 5 μM), and culture the induced cells in a 37°C, 5% CO2 incubator for 36 hours.

[0110] (4) Replace the medium with fresh 1×w / L-glut RPMI 1640 and add retinoic acid (RA). The final concentration of RA in the medium is 1 μM. The induction culture time is 36 hours.

[0111] (5) Replace with fresh 1×w / L-glut RPMI 1640 medium, add Activin-A and fibroblast growth factor 9 (FGF9). The final concentration of Activin-A in the medium is 10 ng / ml, and the final concentration of FGF9 in the medium is 100 ng / mL. Induce culture for 7 days (until the 11th day of culture) to induce secretion of extracellular matrix. During this period, change the medium once a day according to step (5).

[0112] The culture conditions at different induction stages (days, induction culture starts from step (2)) are as follows: Figure 6 shown.

[0113] It can be found that only a very small amount of extracellular matrix can be observed under the microscope after the culture is completed. The inventor believes that the reason may be that only RA was used alone during induction, and the use of RA alone will inhibit the expression of extracellular matrix of pluripotent stem cells to a certain extent. There are also literature reports that RA will inhibit cells from secreting extracellular matrix.

[0114] The collected cells were passed through a 40 μm cell sieve, and the residue on the sieve (the filter residue) was taken, which was the extracellular matrix. A total of 1.9×10 cells were collected. 7 Each cell produced 10 mg of extracellular matrix (wet weight, weigh the material on the sieve). That is, on average, every 10 million cells produced about 5.2 mg of extracellular matrix.

[0115] Test Case

[0116] 10 mg (wet weight) of the extracellular matrix collected in Example 1, Example 2, Comparative Example 2 and Comparative Example 3 were taken as test samples for detection.

[0117] The specific detection steps are as follows: rinse the test sample with pre-cooled PBS buffer for 2 to 3 times, randomly cut it into small pieces and place it in a homogenizer, add 1000 μL tissue protein extraction reagent (purchased from Thermo Scientific, according to the instructions, add protease inhibitors within a few minutes before use), ice bath, and thoroughly homogenize. Transfer the homogenate to a centrifuge tube, oscillate, and ice bath for 30 minutes. During this period, use a pipette to repeatedly blow and beat to ensure that the homogenate is completely lysed. Centrifuge at 4°C, 12000rpm for 5 minutes, collect the supernatant, and obtain the total protein solution. The total protein content is detected using the BCA kit.

[0118] The results are shown in Table 1.

[0119] Table 1

[0120] Group Example 1 Example 2 Comparative Example 2 Comparative Example 3 Detection of total protein concentration (mg / mL) 1.65 1.69 1.21 1.25

[0121] From the above results, it can be found that the protein secretion effect of the extracellular matrix induced by the combination of RA and FGF2 is much higher than that of using a single inducer. The comparison results of each group reflect the synergistic effect of RA and FGF2 in promoting cell protein secretion.

[0122] The type of protein secreted by the extracellular matrix in Example 1 was further detected, and the detection steps were as follows:

[0123] (1) Total protein extraction: Take 10 mg (wet weight) of the extracellular matrix collected in Example 1, rinse the extracellular matrix with pre-cooled PBS buffer for 2 to 3 times, randomly cut into small pieces and place in a homogenizer, add 100 μL of tissue protein extraction reagent (purchased from Thermo Scientific, according to the instructions, add protease inhibitors within a few minutes before use), ice bath, and thoroughly homogenize. Transfer the homogenate to a centrifuge tube, shake, and ice bath for 30 minutes, during which time use a pipette to repeatedly blow and beat to ensure that the homogenate is completely lysed. Centrifuge at 4°C, 12000 rpm for 5 minutes, collect the supernatant, and obtain a total protein solution.

[0124] (2) Western blot detection:

[0125] Sample preparation: Take 40 μL of the total protein solution obtained in step (1), add 10 μL of 5× loading buffer, vortex to mix, and heat at 98°C for 10 min.

[0126] Gel preparation: Fix the clean glass plate, then add the pre-prepared separation gel (10% separation gel), and add water to seal to remove bubbles. After the gel solidifies, use filter paper to absorb the water in the glass plate, then add concentrated gel (5% concentrated gel) and insert a comb. After the gel solidifies again, immerse it in the electrophoresis solution and gently pull out the comb.

[0127] Electrophoresis: The voltage of the concentrated gel is 80 V, and the voltage of the separation gel is 130 V. The electrophoresis ends when the band reaches the bottom of the glass plate.

[0128] Transfer: Activate the PVDF membrane in methanol for 1 min, place the black side of the clamp into a glass dish filled with transfer solution, and place a layer of sponge pad, three layers of filter paper, separation gel, PVDF membrane, three layers of filter paper from bottom to top, and finally cover with a layer of sponge pad, remove bubbles, clamp the clamp, add pre-cooled transfer solution, set the current to 250mA, and transfer the membrane in an ice bath for 1.0h.

[0129] Blocking: Place the PVDF membrane transferred in the previous step into an appropriate amount of 5% skimmed milk powder and shake on a decolorizing shaker for 1 hour.

[0130] Cutting: Cut the PVDF membrane according to the molecular weight of the detected protein.

[0131] Primary antibody incubation: Dilute the primary antibodies (human Collagen I, Collagen II, Collagen III, Collagen IV, laminin, GAG and GAPDH) with primary antibody diluent according to the ratio in the reagent instructions, put the blocked PVDF membrane into a hybridization bag and incubate overnight at 4°C. Wash with TBST 5 times, 5 minutes each time.

[0132] Secondary antibody incubation: Dilute the secondary antibody with 5% skim milk powder according to the reagent instructions. Incubate the membrane in the secondary antibody for 1 hour. Wash with TBST 5 times, 5 minutes each time.

[0133] Luminescence detection: Add freshly prepared ECL mixed solution to the protein side of the membrane for luminescence detection. Adjust the exposure conditions according to different light intensities, develop and save the images.

[0134] The results are as follows Figure 7 shown.

[0135] It can be found that since the sources of some known proteins are certain (such as the proteins of Matrigel matrix Corning matrix glue are derived from mice, and the collagen, laminin and GAG used in western blot are all human), it can be found by comparison that the proteins in the test sample (extracellular matrix in Example 1) must be derived from the extracellular matrix secreted by cells. Therefore, it can be shown that the ECM in Example 1 has an excellent protein secretion effect.

[0136] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for inducing stem cells to secrete extracellular matrix, comprising the following steps: (1) Cultivating cells in a Matrigel-coated cell culture vessel using TeSR1 medium; (2) Change to cell culture medium containing GSK-3α / β inhibitor and culture for 20 to 48 h; (3) Change the cell culture medium to contain retinoic acid and fibroblast growth factor-2 and culture for 20 to 48 hours; (4) The cell culture medium is replaced with one containing activin A and fibroblast growth factor-9 and cultured for at least 1 day to obtain the extracellular matrix.

2. The method according to claim 1, characterized in that The stem cells include human stem cells.

3. The method according to claim 2, characterized in that The human stem cells include human pluripotent stem cells and human embryonic stem cells.

4. The method according to claim 1, characterized in that: In step (2), the GSK-3α / β inhibitor is CHIR99021, and its final concentration in the cell culture medium is 5 to 15 μM.

5. The method according to claim 1, characterized in that In step (3), the final concentration of the retinoic acid in the cell culture medium is 1-10 μM, and the final concentration of the fibroblast growth factor 2 in the cell culture medium is 50 ng-200 ng / mL.

6. The method according to claim 1, characterized in that In step (4), the final concentration of activin A in the cell culture medium is 1-10 ng / mL, and the final concentration of fibroblast growth factor 9 in the stem cell culture medium is 50 ng-200 ng / mL.

7. The method according to claim 1, characterized in that The cell culture medium in steps (2) to (4) includes RPMI 1640 culture medium.

8. An extracellular matrix, characterized in that An extracellular matrix obtained by the method according to any one of claims 1 to 7.

9. Use of the extracellular matrix according to claim 8 in the preparation of a product containing collagen, laminin and / or proteoglycan.

10. The use according to claim 9, characterized in that: The products include medicines, food and cosmetics.

Citation Information

Patent Citations

  • Water-soluble matrix suitable for preparing retinoic acid water-soluble preparation

    CN102038954A

  • Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell

    CN110662832A

  • Method of Differentiating Stem Cells

    US20110008819A1

  • Volume exclusion agent to enhance formation of extracellular matrix

    US20110244570A1